Our areas of partnering interest

In CVRM, our mission is to protect the lives of people from the often devastating consequences of heart failure, cardiovascular, metabolic and renal diseases, so they can enjoy long and fulfilling lives. We are committed to the seamless management of diseases, improving patient outcomes and decreasing the mortality rate.

AstraZeneca is an established leader in respiratory care. We aim to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing chronic obstructive pulmonary disease (COPD) as a top-three leading cause of death. With common pathways and underlying disease drivers across respiratory and immunology, we are following the science from chronic lung diseases to immunology-driven diseases. Our growing presence in immunology is focused on five mid- to late-stage franchises with multi-disease potential in rheumatology (including Systemic Lupus Erythematosus), dermatology, gastroenterology, and systemic eosinophilic-driven diseases. Our ambition is to achieve disease modification and ultimately clinical remission in targeted immune-driven diseases.

We work to protect patients against the burden of influenza, respiratory syncytial virus (RSV) and bacterial infections, particularly those resistant to current antibiotics. Working with the wider infection community, we aim to translate science into solutions to address the global challenges faced in these disease areas.

More than 90 percent of our clinical pipeline now follows a precision medicine approach. We collaborate with a wide range of partners to validate and develop diagnostic devices to regulatory standards globally, and to commercialise innovative biomarker capabilities for patient selection, disease identification and drug response. These collaborations cover a broad range of cutting-edge technologies, such as tumour tissue diagnostics, molecular tests, and point-of-care diagnostics.
 

We are exploring diagnostic tests based on circulating free DNA, also known as liquid biopsy, to measure minimal residual disease in cancer, which could lead to patients being treated at an early stage, when response rates are higher. We are also developing companion diagnostics and point-of-care devices to test patients entering our cardiovascular, renal, metabolism, respiratory and immunology clinical trials, to ensure treatments reach the right patients.

We are interested in cutting-edge technologies to enhance the quality, effectiveness and productivity of our research and translational capabilities.